Evaxion Biotech (EVAX) Price & Analysis

Compare

346 Followers

EVAX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.20 - $17.75

Previous CloseN/A

Volume99.85K

Average Volume (3M)109.56K

Market Cap

$3.89M

Enterprise Value$1.04B

Total Cash (Recent Filing)$4.58M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.76

Next Earnings

Aug 07, 2025

EPS Estimate

-0.58

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding6,316,572

10 Day Avg. Volume132,154

30 Day Avg. Volume109,559

Financial Highlights & Ratios

PEG Ratio0.10

Price to Book (P/B)-0.72

Price to Sales (P/S)0.00

P/FCF Ratio-2.01

Enterprise Value/Market Cap267.18

Enterprise Value/Revenue274.52

Enterprise Value/Gross Profit314.09

Enterprise Value/Ebitda-17.83

Forecast

1Y Price Target

$10.00

Price Target Upside261.01% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Evaxion Biotech News

PremiumThe Fly

Evaxion Biotech receives grant funding to design new polio vaccine

13d ago

EVAX

PremiumThe Fly

U.S. extends EU tariff deadline, Salesforce to acquire Informatica: Morning Buzz

20d ago

PremiumThe Fly

Morning Movers: Informatica and Salesforce gain after $8B transaction

20d ago

AZO

BNS

PremiumThe Fly

Evaxion Biotech reports Q1 EPS (1c) vs. 3c last year

20d ago

EVAX

PremiumThe Fly

Evaxion Biotech sees cash runway into mid-2026

20d ago

EVAX

PremiumThe Fly

Evaxion Biotech sees operational cash burn of $14M in FY25

20d ago

EVAX

PremiumThe Fly

Evaxion Biotech doses first patient in extension of phase 2 trial on EVX-01

25d ago

EVAX

PremiumCompany Announcements

Evaxion Secures Gates Foundation Grant for Innovative Polio Vaccine

13d ago

EVAX

See All EVAX News

See All News >

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe potential cash infusion from Merck's option exercise could extend the company's cash runway into 2027, providing financial stability.

Strategic PartnershipsManagement is on target to announce an infectious disease vaccine, which could aid in attracting additional partnerships and non-dilutive funding.

Technological InnovationEvaxion is one of the pioneers and a front-runner in artificial intelligence (AI)-powered vaccine development.

Bears Say

Market CompetitionThe potential of neoantigen vaccines, like Evaxion’s EVX-01, remains underappreciated, and it has demonstrated strong synergy with pembrolizumab in a Phase 2 study in metastatic melanoma.

Revenue PerformanceEvaxion reported total revenues of $3.3M, which fell short of the consensus estimate of $4.5M.

Risk FactorsRisks to the Buy rating include partnership, technology, clinical, regulatory, commercial, legal and intellectual property, competition, and dilution.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

0.01% Mutual Funds

1.66% Other Institutional Investors

98.33% Public Companies and Individual Investors

Detailed Ownership Overview >

EVAX FAQ

What was Evaxion Biotech’s price range in the past 12 months?

Evaxion Biotech lowest stock price was $1.20 and its highest was $17.75 in the past 12 months.

What is Evaxion Biotech’s market cap?

Evaxion Biotech’s market cap is $3.89M.

When is Evaxion Biotech’s upcoming earnings report date?

Evaxion Biotech’s upcoming earnings report date is Aug 07, 2025 which is in 52 days.

How were Evaxion Biotech’s earnings last quarter?

Evaxion Biotech released its earnings results on May 27, 2025. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.01.

Is Evaxion Biotech overvalued?

According to Wall Street analysts Evaxion Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Evaxion Biotech pay dividends?

Evaxion Biotech does not currently pay dividends.

What is Evaxion Biotech’s EPS estimate?

Evaxion Biotech’s EPS estimate is -0.58.

How many shares outstanding does Evaxion Biotech have?

Evaxion Biotech has 6,316,572 shares outstanding.

What happened to Evaxion Biotech’s price movement after its last earnings report?

Evaxion Biotech reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 25.532%.

Which hedge fund is a major shareholder of Evaxion Biotech?

Currently, no hedge funds are holding shares in EVAX

Company Description

Evaxion Biotech

Evaxion Biotech (EVAX) is a biotechnology company that specializes in the development of AI-driven immunotherapies. Operating primarily in the healthcare and biotechnology sectors, Evaxion leverages its proprietary artificial intelligence platforms to discover and design novel vaccines and other immune-related therapies. The company's core focus is on developing treatments for cancer, bacterial diseases, and viral infections, utilizing its innovative technology to accelerate the drug discovery process.

EVAX Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive outlook with strong R&D progress and a promising partnership with Merck, despite challenges posed by financial market uncertainties affecting deal execution.Read More>

EVAX Stock 12 Month Forecast

Average Price Target

$10.00

▲(261.01%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","16":"$16","32":"$32","48":"$48","64":"$64"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,16,32,48,64],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.56,2.516923076923077,3.4738461538461536,4.430769230769231,5.387692307692308,6.344615384615384,7.3015384615384615,8.258461538461539,9.215384615384615,10.172307692307692,11.12923076923077,12.086153846153847,13.043076923076923,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.56,2.209230769230769,2.8584615384615386,3.5076923076923077,4.156923076923077,4.806153846153846,5.455384615384615,6.104615384615384,6.753846153846153,7.403076923076922,8.052307692307691,8.70153846153846,9.350769230769231,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.56,1.9015384615384616,2.243076923076923,2.5846153846153843,2.926153846153846,3.2676923076923075,3.609230769230769,3.9507692307692306,4.292307692307692,4.633846153846154,4.975384615384615,5.316923076923077,5.6584615384615375,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.95,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.35,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.25,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >